• Orexo released the transcript of its Q2 2026 earnings call attended by CEO Nikolaj Sorensen and CFO Fredrik Jarrsten.
• Management flagged elevated Q2 cash outflow tied to legacy Zubsolv rebates; own cash SEK 233 million, with SEK 44 million payable to Dexcel.
• OPEX totaled SEK 107 million, inflated by a GAIA settlement of about SEK 20 million and higher DOJ-related legal fees; normalized OPEX seen near SEK 60 million.
• DOJ talks described as more constructive, with settlement payments expected over several years; parts potentially covered by D&O insurance for individuals.
• Izipry filing targeted for September with a 6-month FDA review; OX640 pivotal plan centers on nasal allergy challenge in Q4 2026, with about SEK 200 million to filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.